 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682706 |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.035.745 |
| Chemical and physical data | |
| Formula | C24H25NO4 |
| Molar mass | 391.467 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Flavoxate is ananticholinergic withantimuscarinic effects. Itsmuscle relaxant properties may be due to a direct action on the smooth muscle rather than by antagonizing muscarinic receptors.
Flavoxate is used to treat urinary bladder spasms. It is available under the trade name Urispas (Paladin)(india), Genurin (by Recordati, Italy) in Italy and KSA, Uritac by El Saad company in Syria, under the name Bladderon byNippon Shinyaku of Japan, or Bladuril in Chile, Utispas ( Apex Pharma) in Nepal.
Flavoxate is indicated for symptomatic relief ofinterstitial cystitis, dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.
Flavoxate is generally well tolerated, but can potentially cause vomiting, upset stomach, dry mouth or throat, blurred vision, eye pain,[1] and increased sensitivity of the eyes to light.
Flavoxate is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.